Publications
Articles
- Aquilanti, E. et al. 2023. Telomerase inhibition is an effective therapeutic strategy in TERT promoter mutant-glioblastoma models with low tumor volume. Neuro-Oncology 25(7), pp. 1275-1285. (10.1093/neuonc/noad024)
- Rastogi, N. et al. 2021. Use of an anti-CD200 blocking antibody improves immune responses to AML in vitro and in vivo. British Journal of Haematology 193(1), pp. 155-159. (10.1111/bjh.17125)
- Robinson, A. J. et al. 2020. Reactive oxygen species drive proliferation in acute myeloid leukemia via the glycolytic regulator PFKFB3. Cancer Research 80(5), pp. 937-949. (10.1158/0008-5472.CAN-19-1920)
- Alanazi, B. et al. 2020. Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia. Leukemia 34(2), pp. 427-440. (10.1038/s41375-019-0596-4)
- Zabkiewicz, J. et al. 2016. The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias. Oncotarget 7(13), pp. 16650-16662. (10.18632/oncotarget.7692)
- Daud, S. S. et al. 2012. Identification of the Wnt signalling protein, TCF7L2 as a significantly overexpressed transcription factor in AML [Abstract]. Blood 120(21), article number: 1281.
Thesis
Supervision
Past projects